Whitney J. Palmer

Lutikizumab does not improve pain or imaging outcomes for patients with erosive hand osteoarthritis, according to new research.

While gout does not increase the risk of death post-acute coronary syndrome, a new study shows the condition does increase an individual’s risk for readmission after heart failure, as well as the number of days he or she will spend on the hospital.

Patients with systemic sclerosis-associated interstitial lung disease who also take nintedanib experience a lower drop in their forced vital capacity, according to a new study.

Etanercept is a safe, well-tolerated medication for treating pediatric patients with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and psoriatic arthritis, according to the results for a new study.

Despite being the most common form of inflammatory arthritis, gout continues to be poorly managed, new research indicates.

Obese patients with osteoarthritis who take metformin have a slower rate of medial cartilage loss, putting them at a reduced risk for total knee replacement, a new study found.

Racial and ethnic minority patients with lupus develop more kidney, neurological, and blood manifestations than their white counterparts, according to new research.

Despite recommendations against using opioids and benzodiazepines to treat osteoarthritis pain, new research shows significant numbers of patients, especially older patients, are still receiving prescriptions for these medications.

Psoriasis patients have a lower risk of serious infection with specific biologic and non-biologic medications than with methotrexate, based on new research results.

Getting more exercise can reduce a woman’s risk of developing rheumatoid arthritis, according to new research.

From a new biosimilar to a first-ever approved drug to treat pediatric lupus patients, the Food & Drug Administration has approved several new medications in recent months. In this slideshow, we offer a brief overview of these new therapeutics.

Real-world applications of non-biologic treatments in children with juvenile idiopathic arthritis may be effective in controlling or maintaining the condition in some patients, new research shows.

Glucocorticoids are highly effective in treating inflammatory conditions. However, these medications also pose a significant risk for bone loss and fracture. In this slideshow, we cover the treatment guidelines.

To help clinicians manage antirheumatic drug therapy, the ACR and the American Association of Hip and Knee Surgeons developed evidence-based guidelines for the perioperative management of antirheumatic medication for patients with rheumatic diseases undergoing knee or hip surgery. In this slideshow, we outline those recommendations.

The JAK inhibitor tofacitinib presents a comparably low risk of venous thromboembolism to rheumatoid arthritis patients as do TNFi inhibitors, according to a new study.

Tofacitinib 5 mg or 10 mg twice daily with methotrexate can sustain improvements for 24 months, one study shows.

Baricitinib treatment does not increase the risk for cardiovascular problems in patients with rheumatoid arthritis, according to new research.

Rheumatoid arthritis patients taking tofacitinib could face some increased risks for significant cardiovascular events, depending upon their underlying characteristics, according to the results of a new study.

Children affected by juvenile idiopathic arthritis, manifesting as non-systemic polyarthritis, sacroilitis or enthesitis, have a number of therapeutic options available. In this article, we outline the options.

Identifying the type of depression present in an individual with or at-risk for symptomatic knee osteoarthritis can help clinicians best target therapies to reduce pain and disability over time, according to a new study.

Adding acupuncture to topical ibuprofen can provide greater pain relief for patients with osteoarthritis who have chronic knee pain than treating them with only topical ibuprofen, according to recent research.

Patients with giant cell arteritis treated weekly or bi-weekly with tocilizumab and a prednisone taper experience better outcomes than those treated only with prednisone, a new study shows.

Patients affected by psoriatic arthritis may benefit from both pharmacologic and non-pharmacologic treatments. In this slideshow, we outline the recommendations from the ACR and the National Psoriasis Foundation.

Osteoarthritis patients over age 50 could face a greater risk of mortality after receiving an initial tramadol prescription compared to various commonly prescribed NSAIDS, according to new research.

Rheumatoid arthritis patients and rheumatology providers share many of the same concerns over obstacles that make it harder to reach treat-to-target goals, according to a new study.

Osteoarthritis and rheumatoid arthritis patients report having similar pain levels in the beginning, but by six months, osteoarthritis patients say their pain is worse. This suggests a need for more effective osteoarthritis treatments, say researchers writing in Arthritis & Rheumatology. In this Q&A, the study’s lead author, Theodore Pincus, M.D., of Rush University Medical Center in Chicago, shares his findings with us.

A new systematic review and meta-analysis shows that while NSAIDs peaks at two weeks, while gastrointestinal and cardiovascular adverse events linger.

To help clinicians provide guidance to patients interested in cannabis therapies, the Canadian Rheumatology Association has issued a position statement. In this slideshow, we highlight the recommendations.

Study shows there is no substantial difference in cardiovascular risk associated with different biologic therapies for psoriasis and psoriatic arthritis patients.

In chronic low back pain patients, spinal manipulation therapy can be equally effective at relieving pain and better at providing short-term function improvement compared to recommended treatments, according to recent research.